Literature DB >> 21505920

Extreme values of maternal serum analytes in second trimester screening: looking beyond trisomy and NTD's.

Elizabeth McPherson1, Ginger D Thomas, Christopher Manlick, Christina A Zaleski, Kara K Reynolds, Kristen Rasmussen, Philip F Giampietro, Carmen Wiley, Maria Mascola.   

Abstract

Second trimester maternal serum screening can identify high risk pregnancies and fetuses at risk for birth defects (in addition to those in the standard interpretation). The purpose of this study was to quantify such risks to improve counseling. We compared outcomes of 692 pregnancies that had abnormal levels of at least one analyte with a cohort of 713 pregnancies with normal analytes. Increased risks include: demise with high AFP and low uE3; intrauterine growth restriction with high AFP, high and low hCG, and low uE3; placental abnormalities with high AFP; fetal stress with high AFP and high hCG. Birth defects are increased with high AFP, high hCG, and low hCG. When two or more analytes are abnormal, 46% have a poor outcome. Abnormal levels of maternal serum analytes provide information in addition to the risks for neural tube defects, Down syndrome, and trisomy 18. This information is important for counseling and pregnancy management.

Entities:  

Mesh:

Year:  2011        PMID: 21505920     DOI: 10.1007/s10897-011-9364-y

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  12 in total

Review 1.  Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses.

Authors:  L A Bradley; G E Palomaki; G J Knight; J E Haddow; J M Opitz; M Irons; R I Kelley; G S Tint
Journal:  Am J Med Genet       Date:  1999-02-12

2.  Abnormal multiple marker screens are associated with adverse perinatal outcomes in cases of intrauterine growth restriction.

Authors:  John G Ilagan; David M Stamilio; Serdar H Ural; George A Macones; Anthony O Odibo
Journal:  Am J Obstet Gynecol       Date:  2004-10       Impact factor: 8.661

3.  Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome(1).

Authors:  T G Krause; P Christens; J Wohlfahrt; U Lei; T Westergaard; B Nørgaard-Pedersen; M Melbye
Journal:  Obstet Gynecol       Date:  2001-02       Impact factor: 7.661

4.  Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome.

Authors:  Wendy Y Craig; James E Haddow; Glenn E Palomaki; Richard I Kelley; Lisa E Kratz; Cedric H L Shackleton; Josep Marcos; G Stephen Tint; Andrew R MacRae; Malgorzata J Nowaczyk; Edward M Kloza; Mira B Irons; Marie Roberson
Journal:  Prenat Diagn       Date:  2006-09       Impact factor: 3.050

5.  Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.

Authors:  Ningwu Huang; Amit V Pandey; Vishal Agrawal; William Reardon; Pablo D Lapunzina; David Mowat; Ethylin Wang Jabs; Guy Van Vliet; Joseph Sack; Christa E Flück; Walter L Miller
Journal:  Am J Hum Genet       Date:  2005-03-25       Impact factor: 11.025

6.  Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data.

Authors:  A Milunsky; S S Jick; C L Bruell; D S MacLaughlin; Y K Tsung; H Jick; K J Rothman; W Willett
Journal:  Am J Obstet Gynecol       Date:  1989-08       Impact factor: 8.661

7.  Quad screen as a predictor of adverse pregnancy outcome.

Authors:  Lorraine Dugoff; John C Hobbins; Fergal D Malone; John Vidaver; Lisa Sullivan; Jacob A Canick; Geralyn M Lambert-Messerlian; T Flint Porter; David A Luthy; Christine H Comstock; George Saade; Keith Eddleman; Irwin R Merkatz; Sabrina D Craigo; Ilan E Timor-Tritsch; Stephen R Carr; Honor M Wolfe; Mary E D'Alton
Journal:  Obstet Gynecol       Date:  2005-08       Impact factor: 7.661

8.  First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes.

Authors:  Lorraine Dugoff
Journal:  Obstet Gynecol       Date:  2010-05       Impact factor: 7.661

9.  Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy.

Authors:  Koraljka Duric; Snjezana Skrablin; Josko Lesin; Drzislav Kalafatic; Ivan Kuvacic; Ernest Suchanek
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2003-09-10       Impact factor: 2.435

10.  Isolated low second-trimester maternal serum beta-human chorionic gonadotropin is not associated with adverse pregnancy outcome.

Authors:  Loraine K Endres; Stephan Krotz; William A Grobman
Journal:  Am J Obstet Gynecol       Date:  2003-09       Impact factor: 8.661

View more
  4 in total

1.  Genetic counselors' experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy.

Authors:  Julie M H Horsting; Stephen R Dlouhy; Katelyn Hanson; Kimberly Quaid; Shaochun Bai; Karrie A Hines
Journal:  J Genet Couns       Date:  2013-12-19       Impact factor: 2.537

2.  Mid-trimester maternal serum HCG and alpha fetal protein levels: clinical significance and prediction of adverse pregnancy outcome.

Authors:  Georgios Androutsopoulos; Panagiotis Gkogkos; Georgios Decavalas
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

3.  Correlation of pregnancy outcome with quadruple screening test at second trimester.

Authors:  Shahla Yazdani; Rahele Rouholahnejad; Nesa Asnafi; Majid Sharbatdaran; Marziihe Zakershob; Zinatossadat Bouzari
Journal:  Med J Islam Repub Iran       Date:  2015-10-19

Review 4.  Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening.

Authors:  Amy Metcalfe; Catriona Hippman; Melanie Pastuck; Jo-Ann Johnson
Journal:  J Clin Med       Date:  2014-04-08       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.